ReviewFEMS yeast research2026
Engineering yeast for sustainable bioproduction of tryptophan-derived aromatic compounds.
Review in FEMS yeast research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transcriptional regulation: efficient genetic engineering tools for non-conventional yeasts.FEMS yeast research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Aromatic compounds are a diverse group of bioactive molecules with broad applications in the polymer, food, feed, cosmetic, and pharmaceutical industries. To address climate change and the depletion of fossil resources, there is growing interest in their sustainable production. Yeast cell factories offer an attractive alternative to conventional chemical synthesis by converting aromatic amino acids (AAAs) into a broad range of valuable aromatic products. Among AAAs, L-tryptophan (Trp) is distinguished by its indole moiety and serves as a key precursor for numerous high-value natural products. This review summarises recent advances in the engineering of yeast to produce tryptophan-derived compounds. Furthermore, it discusses current metabolic engineering strategies, synthetic biology tools, and the remaining challenges that must be overcome to achieve efficient, scalable, and economically viable biosynthesis of tryptophan-derived aromatic compounds in yeast.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.